Logo image of QURE

UNIQURE NV (QURE) Stock Price, Quote, News and Overview

NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD

14.42  +0.14 (+0.98%)

After market: 14.42 0 (0%)

QURE Quote, Performance and Key Statistics

UNIQURE NV

NASDAQ:QURE (7/3/2025, 8:02:54 PM)

After market: 14.42 0 (0%)

14.42

+0.14 (+0.98%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High19.18
52 Week Low3.76
Market Cap789.50M
Shares54.75M
Float49.75M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-31 2025-07-31/bmo
IPO02-05 2014-02-05


QURE short term performance overview.The bars show the price performance of QURE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

QURE long term performance overview.The bars show the price performance of QURE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200

The current stock price of QURE is 14.42 USD. In the past month the price decreased by -3.61%. In the past year, price increased by 275.52%.

UNIQURE NV / QURE Daily stock chart

QURE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.34B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.44 139.01B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.03B
REGN REGENERON PHARMACEUTICALS 12.35 59.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.28B
ARGX ARGENX SE - ADR 94.52 33.18B
ONC BEONE MEDICINES LTD-ADR 6.26 26.57B
BNTX BIONTECH SE-ADR N/A 26.44B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.4 19.47B
SMMT SUMMIT THERAPEUTICS INC N/A 18.23B

About QURE

Company Profile

QURE logo image uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Company Info

UNIQURE NV

Paasheuvelweg 25a

Amsterdam NOORD-HOLLAND 1105 BP NL

CEO: Matthew Kapusta

Employees: 209

QURE Company Website

QURE Investor Relations

Phone: 31202406000

UNIQURE NV / QURE FAQ

What is the stock price of UNIQURE NV today?

The current stock price of QURE is 14.42 USD. The price increased by 0.98% in the last trading session.


What is the ticker symbol for UNIQURE NV stock?

The exchange symbol of UNIQURE NV is QURE and it is listed on the Nasdaq exchange.


On which exchange is QURE stock listed?

QURE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for UNIQURE NV stock?

20 analysts have analysed QURE and the average price target is 37 USD. This implies a price increase of 156.58% is expected in the next year compared to the current price of 14.42. Check the UNIQURE NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UNIQURE NV worth?

UNIQURE NV (QURE) has a market capitalization of 789.50M USD. This makes QURE a Small Cap stock.


How many employees does UNIQURE NV have?

UNIQURE NV (QURE) currently has 209 employees.


What are the support and resistance levels for UNIQURE NV (QURE) stock?

UNIQURE NV (QURE) has a support level at 14.29 and a resistance level at 14.43. Check the full technical report for a detailed analysis of QURE support and resistance levels.


Is UNIQURE NV (QURE) expected to grow?

The Revenue of UNIQURE NV (QURE) is expected to decline by -47.3% in the next year. Check the estimates tab for more information on the QURE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy UNIQURE NV (QURE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UNIQURE NV (QURE) stock pay dividends?

QURE does not pay a dividend.


When does UNIQURE NV (QURE) report earnings?

UNIQURE NV (QURE) will report earnings on 2025-07-31, before the market open.


What is the Price/Earnings (PE) ratio of UNIQURE NV (QURE)?

UNIQURE NV (QURE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.41).


What is the Short Interest ratio of UNIQURE NV (QURE) stock?

The outstanding short interest for UNIQURE NV (QURE) is 15.42% of its float. Check the ownership tab for more information on the QURE short interest.


QURE Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to QURE. When comparing the yearly performance of all stocks, QURE is one of the better performing stocks in the market, outperforming 98.31% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

QURE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to QURE. Both the profitability and financial health of QURE have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QURE Financial Highlights

Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.94%
ROE -645.89%
Debt/Equity 14.79
Chartmill High Growth Momentum
EPS Q2Q%39.71%
Sales Q2Q%-81.53%
EPS 1Y (TTM)29%
Revenue 1Y (TTM)6.43%

QURE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to QURE. The Buy consensus is the average rating of analysts ratings from 20 analysts.

For the next year, analysts expect an EPS growth of 26.42% and a revenue growth -47.3% for QURE


Ownership
Inst Owners91.37%
Ins Owners1.66%
Short Float %15.42%
Short Ratio4.01
Analysts
Analysts84
Price Target37 (156.59%)
EPS Next Y26.42%
Revenue Next Year-47.3%